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Abstract
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although
survival rates have improved, patients with certain biological subtypes still have suboptimal
outcomes. Current chemotherapeutic regimens are associated with short- and long-term toxicities
and novel, less toxic therapeutic strategies are needed. Mer receptor tyrosine kinase is ectopically
expressed in ALL patient samples and cell lines. Inhibition of Mer expression reduces pro-survival
signaling, increases chemosensitivity, and delays development of leukaemia in vivo suggesting
that Mer tyrosine kinase inhibitors are excellent candidates for targeted therapies. Brain and spinal
tumors are the second most common malignancies in childhood. Multiple chemotherapy
approaches and radiation have been attempted, yet overall survival remains dismal. Mer is also
abnormally expressed in atypical teratoid/rhabdoid tumors (ATRT), providing a rationale for
targeting Mer as a therapeutic strategy. We have previously described UNC569, the first small
molecule Mer inhibitor. This manuscript describes the biochemical and biological effects of
UNC569 in ALL and ATRT. UNC569 inhibited Mer activation and downstream signaling through
ERK1/2 and AKT, determined by western blot analysis. Treatment with UNC569 reduced
proliferation/survival in liquid culture, decreased colony formation in methylcellulose/soft agar,
and increased sensitivity to cytotoxic chemotherapies. MYC transgenic zebrafish with T-ALL
were treated with UNC569 (4 µM for 2 weeks). Fluorescence was quantified as indicator of the
distribution of lymphoblasts, which express Mer and enhanced green fluorescent protein. UNC569
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induced >50% reduction in tumor burden compared to vehicle- and mock-treated fish. These data
support further development of Mer inhibitors as effective therapies in ALL and ATRT.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and
represents nearly 30% of all pediatric cancers (1;2). Although the overall survival rate for
pediatric B-cell ALL is approximately 85%, specific biological subtypes, including T-ALL,
have a poorer prognosis even with current therapeutic protocols and treatment of relapsed
ALL remains a challenge (3). In addition, the intensified therapy used in current protocols is
associated with a significant and increased risk for short- and long-term toxicities (slowed
growth, organ damage, and secondary malignancy) (4;5). Therefore, novel, more effective,
and less toxic therapies are needed.
Tyrosine kinases are frequently abnormally regulated in cancer cells. Overexpression of Mer
receptor tyrosine kinase, a member of the TAM (Tyro3/Axl/Mer) family of receptor tyrosine
kinases, has been reported in a variety of human cancers, including B- and T- ALL (6–8).
Ectopic expression of Mer in lymphocytes in transgenic mice promotes the development of
leukemia/lymphoma (9;10). In humans, Mer is ectopically expressed in pediatric T-cell ALL
and pre-B-cell ALL patient samples. In contrast, Mer is not expressed in normal mouse and
human T- and B-lymphocytes at any stage of development (11). Inhibition of Mer
expression by shRNA has been shown to reduce pro-survival signaling, dramatically
increase the sensitivity of leukemia cells to cytotoxic agents, and significantly delay
development of leukemia in a mouse model (12;13). Taken together, these data provide a
rationale for targeting Mer as a therapeutic strategy in ALL.
Brain and spinal tumors are the second most common malignancies in childhood after
leukemia (14). Atypical teratoid rhabdoid tumors (ATRTs) are rare tumors of the central
nervous system. However, in patients less than 3 years of age this tumor accounts for up to
20% of cases. Multiple chemotherapy approaches and radiation have been attempted, yet
overall survival remains dismal (15). This aggressive tumor remains a significant challenge
in pediatric neuro-oncology, and new therapeutic approaches are needed. The abnormal
expression of Mer in ATRT cells provides a rationale for targeting Mer as a therapeutic
strategy in this aggressive cancer type.
In the past several years, tyrosine kinase inhibitors (TKI) have taken on an increasingly
important role in the treatment of cancer. Imatinib, a selective inhibitor of the BCR-ABL
tyrosine kinase most impressively validated the concept of designing a small molecule TKI
to treat a defined patient population. The improvement in survival has been dramatic in
chronic myeloid leukaemia, which is driven by the BCR-ABL translocation (16). Because
some patients experienced relapse due to resistance-conferring point mutations within BCR-
ABL, the second-generation ABL kinase inhibitors nilotinib and dasatinib were developed
and other ABL kinase inhibitors with activity against BCR-ABL (T315I) including
ponatinib are being investigated (17;18). Other examples of small molecule TKI under
investigation are vandetanib in the management of medullary thyroid cancer (19), lapatinib
for the treatment of hormone-positive and HER2-positive advanced breast cancer (20),
erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer (21),
sunitinib for the treatment of metastatic renal cell carcinoma (22), sorafenib against acute
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myeloid leukemia (23) and vemurafenib against melanoma with BRAF V600E mutation
(24).
Targeted therapy aimed at a specific cancer-promoting signaling pathway is expected to
allow for a more efficacious clinical response in patients with ALL and significantly reduce
toxicities. Recent successes in the treatment of cancer with small molecule TKI has
encouraged us to develop a small molecule Mer tyrosine kinase inhibitor (Mer TKI) as a
selective therapeutic for ALL (25;26). We have previously reported the first in class Mer-
selective small molecule inhibitor UNC569 (27). UNC569 (Figure 1) is a
pyrazolopyrimidine with potent activity against Mer (Mer IC50 = 2.9 nM, Axl IC50=37 nM,
Tyro3 IC50 = 48 nM). The studies described here demonstrate anti-oncogenic properties
mediated by UNC569 in ALL cell lines, in a transgenic zebrafish T-ALL model and in
atypical teratoid rhabdoid tumors.
Materials and Methods
Tissue culture
Jurkat (T-ALL) and 697 (B-ALL) human leukemia cell lines were obtained from the
American Type Culture Collection, ATCC (Manassas, VA) and from the German Collection
of Microorganisms and Cell Cultures, DSMZ (Braunschweig, Germany). These cell lines
were cultured in RPMI-1640 media (Hyclone Laboratories, Logan, UT) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and penicillin/
streptomycin (100 units/ml and 100 µg/ml, Hyclone Laboratories, Logan, UT). The atypical
teratoid rhabdoid tumor cell line, BT12 were obtained from Bernard Weissman (UNC
Lineberger) and were grown in RPMI-1640 media supplemented with 15% fetal bovine
serum and penicillin/streptomycin (100 units/ml and 100 µg/ml). Cells were maintained at
37°C in a humidified atmosphere containing 5% CO2. The 697 and the Jurkat cell lines were
authenticated. The identities of 697 (6/2012) and Jurkat (12/2012) cell lines were confirmed
by short tandem repeat analysis (28) and matched with the information in the DSMZ
database. At this time there is no STR profile publicly available for the BT12 cell line.
However the STR profiles (12/2012) are singular and do not match any in the ATCC or
DSMZ collections. All cell cultures were tested negative for mycoplasma contamination.
Recombinant human growth arrest-specific protein 6 (Gas6) (#885-GS, R&D Systems,
Minneapolis, MN) was reconstituted in PBS. Inhibitor UNC569 was synthesized as
previously described (27) and stock solutions were prepared in DMSO at 3 mM.
Immunoprecipitation and detection of phosphorylated Mer
ALL cell cultures were treated with 0.12 mM pervanadate for 3 minutes to stabilize the
phosphorylated form of Mer. Cells were lysed in 50 mM HEPES (pH 7.5), 150 mM NaCl,
10 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate,
0.1 mM sodium molybdate, and protease inhibitors (Complete mini, Roche Molecular
Biochemicals, Indianapolis, IN) and Mer was immunoprecipitated by incubating with mouse
monoclonal anti-Mer antibody (MAB8912, R&D Systems, Minneapolis, MN) and rec-
Protein G-sepharose 4B beads (#10-1242, Invitrogen, Grand Island, NY). Immune
complexes were collected by centrifugation and washed with lysis buffer. Beads were
resuspended in Laemmli buffer (62.5 mM Tri-HCl pH 6.8, 25% glycerol, 5% β-
mercaptoethanol, 2% SDS, and 0.01% bromophenol blue) and boiled to elute bound protein.
Phosphorylated and total Mer proteins were detected by western blot using a proprietary α-
phospho Mer antibody (29) (PhosphoSolutions, Aurora, CO) and anti-human Mer antibody
(#1633-1, Epitomics, Burlingame, CA). To determine the relative changes in
phosphorylation between UNC569-treated and untreated cells, the densities of individual
bands were measured using ImageJ software (National Institute of Health). IC50 values were
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determined by non-linear regression using GraphPad Prism software (v5.0, GraphPad
Software, LaJolla, CA). BT12 cells were pre-incubated with the indicated UNC569
concentration followed by treatment with pervanadate as above. Cells were lysed,
immunoprecipitated with polyclonal C-terminal Mer antibody N-14 (30) and subjected to
SDS-polyacrylamide gel electrophoresis.
Western blot analysis
Whole cell lysates were prepared and resolved by SDS-PAGE. The following antibodies
from Cell Signaling Technology (Danvers, MA) were used for western blot analysis
according to manufacturer recommendations: anti-phospho-Akt (Ser473, #9271), anti-Akt
(#9272); anti-phospho-p44/42 MAPK (pErk1/2, Thr202/Tyr204, #9106), anti-p44/42
MAPK (Erk1/2, #9102), anti-PARP (#9542), anti-Caspase 3 (#9662), anti-Tubulin (#2125),
anti-Tyro3 (#5585) and anti-GAPDH (#3683, HRP). Anti-Actin antibody (#sc-1616 HRP)
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Anti-Axl antibody
(#AF154) was purchased from R&D Systems. Primary antibodies were labeled with HRP-
conjugated secondary antibodies (donkey-anti-goat, #sc-2020, Santa Cruz Biotechnology;
goat-anti-mouse, #170-6516, Bio-Rad Laboratories, Hercules, CA; or donkey-anti-rabbit,
#711-035-152, Jackson ImmunoResearch Laboratories, West Grove, PA) and proteins were
visualized by enhanced chemiluminescence (Perkin-Elmer, Waltham, MA). For BT12
experiments gels with electrophoresed, Mer immunoprecipitates were transferred and
blotted with phosphotyrosine antibody (#sc-508 HRP) or back blotted with the NIH anti-
Mer polyclonal.
Colorimetric assay for detection of metabolically active cells
Jurkat and 697 cells were plated at optimal density in 96-well plates (3 × 105 cells/ml) and
cultured for 8 hours before addition of UNC569 or an equivalent volume of DMSO control.
After 24 hours cells were harvested and plated in fresh medium containing UNC569 or
vehicle only for an additional 24 hours. MTT reagent (3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide, #M5655 Sigma, St. Louis, MO) was added to a final
concentration of 0.65 mg/ml and the cells were incubated for another 4 hours. Solubilization
solution (2×, 10% sodium duodecyl sulfate in 0.01 M HCl) was added and plates were
incubated at 37°C overnight. Optical density was determined at 562 nm with a reference
wavelength of 650 nm. BT12 cells were plated at optimal density in 96 well plates (5 × 103
cells/ml) and cultured for 8 hours before addition of UNC569 or an equivalent volume of
DMSO control. After 48 hours, 20 µl of MTS (3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent (Cell Titer 96 Aqueous
One Solution Reagent #G3582, Promega, Madison, WI) was added to each well. The cells
were incubated for 4 hours. Absorbance was recorded at 490 nm using a 96-well plate
reader. Relative cell numbers for all cell lines were calculated by subtraction of background
absorbance and normalization to untreated controls. IC50-values were determined by
nonlinear regression using GraphPad Prism software.
Apoptosis assay
Jurkat or 697 cells were plated at 3 × 105 cells/ml and treated with UNC569 and/or cytotoxic
agents (methotrexate, #A6770, Sigma, St. Louis, MO; etoposide, #341205, CalBiochem,
Billerica, MA) for 48 hours. Alternatively, cells were treated with UNC569 for 24 hours,
then harvested and cultured in fresh medium containing UNC569 or vehicle only for an
additional 24 hours. Cells were collected by centrifugation at 240g for 5 minutes. Cell
pellets were resuspended in PBS containing 1 µM YO-PRO-1 (Y3603, Invitrogen, Grand
Island, NY) and 1.5 µM propidium iodide (P3566, Invitrogen). Samples were incubated for
15 minutes and fluorescence was detected using a FC500 flow cytometer and analyzed with
CXP data analysis software (Beckman Coulter, Krefeld, Germany).
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Jurkat or 697 cells were plated in methylcellulose-based medium (#1101, ReachBio, Seattle,
WA) containing UNC569 or DMSO control according to manufacturer’s protocol (500 cells/
ml methylcellulose, 35 mm plates). After the initial plating, additional UNC569 or DMSO
control was added to the top of the methylcellulose in a volume of 100 µl every other day.
Colonies were grown for eight days and then counted. Bright field images were taken with a
spinning disk confocal 3I Marianas (Intelligent Imaging Innovations Inc., Denver, CO)
based on a inverted Zeiss Axio Observer Z1 (Carl Zeiss Inc., Jenna, Germany). A CoolSnap
HQ2 camera featuring 1392 × 1040 imaging pixels (Photometrics Inc., Tucson, AZ) via a 5×
Zeiss air objective was used. As imaging acquisition software Slidebook 5.0 (Intelligent
Imaging Innovations, Inc., Denver, CO) was utilized. Single colony pictures were generated
using a Nikon Eclipse TS100 microscope (Nikon Inc., Melville, NY) with Nikon Plan 10X,
numerical aperture 0.25 objective lens and with a Nikon Digital Sight DS-L2 camera
equipped with Firmware DS-L2 Ver4.60.
Soft agar assay
BT12 cells were plated in 0.7% agarose (#CA3510-8 Denville Scientific, South Plainfield,
NJ) over a higher percentage agar base layer. Agarose was overlaid with medium
(RPMI-1640 media supplemented with 15% fetal bovine serum and penicillin/streptomycin
(100 units/ml and 100 µg/ml)) with UNC569. Medium and UNC569 were renewed twice
weekly. Colonies were grown for 14 days prior to staining with 2 mg/ml MTT (#M5655,
Sigma). Representative pictures are scans made with Perfection V700 Scanner (Epson, Long
Beach, CA) and subsequent counting using ImageJ Software.
Leukemic zebrafish experiments
Transgenic zebrafish expressing human MYC in lymphocytes (31) were crossed to
lck::EGFP zebrafish (32). Leukemic fish were identified via fluorescence microscopy and
images were captured using an Olympus MVX10 Microscope with a SPOT Insight Camera
and software package. Zebrafish with cancer were then treated by “immersion assay,” as
described previously (33). Briefly, fish were housed in 4 µM UNC569 plus DMSO,
equimolar DMSO vehicle alone, or water only. Daily water changes with fresh drug were
performed for a treatment duration of 14 days. Fluorescent images were captured at day 14
for comparison to pre-treatment images. Images were normalized to an internal reference
standard. Fluorescence intensity was determined using ImageJ software and plotted as a
three-dimensional spatial representation for each image. Plots were integrated to generate
volumetric quantifications of the area under the curve. GFP fluorescence was compared in
the same fish pre- and post-treatment to assess responses, reflected as per cent gain or loss in
GFP intensity (termed the “GFP score”).
Statistical analyses
Statistically significant differences between means were determined using a two-tailed,
unpaired Student’s t-tests for zebrafish and cell culture experiments, respectively. The level
of significance for all statistical analyses was chosen a priori to be p < 0.05. Statistical
analyses were carried out using GraphPad Prism software (Version 5.0, GraphPad Software,
LaJolla, CA).
Results
UNC569 inhibits Mer and downstream oncogenic signaling pathways in ALL cells
Activation of Mer stimulates proliferative and anti-apoptotic signaling, including the PI3K/
AKT and MAPK/ERK pathways (12;29). Western blot analysis was used to determine
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inhibition of Mer (phospho-Mer) in response to treatment with UNC569 and effects on
downstream oncogenic signaling pathways in ALL cells. ALL cells were treated with
UNC569 and a dose-dependent decrease in the levels of the active, phosphorylated form of
Mer was observed in both 697 B-cell ALL (IC50 = 141 ± 15 nM) and Jurkat T-cell ALL
(IC50 = 193 ± 56 nM) cells (Figures 2A and B). Mer inhibition was achieved with lower
UNC569 doses in the 697 cell line compared to the Jurkat cell line (Figure 2A). The Jurkat
cell line expressed Mer and Tyro3, but no Axl (Supplementary figure 1). To demonstrate
specificity for Mer, we tested whether UNC569 inhibited the activation of Tyro3 (phospho-
Tyro3) in addition to Mer. Jurkat cells were treated with UNC569 and no decrease in the
levels of the active, phosphorylated form of Tyro3 was detected (Supplementary figure 2),
suggesting that any phenotypic effects noted from UNC569 were not mediated via inhibition
of the closely related Axl or Tyro3 tyrosine kinases.
Decreased Gas6 ligand-stimulated phosphorylation of ERK was observed in Jurkat cells
treated with UNC569 relative to cells treated with vehicle only (Figure 2C). In the 697 cell
line, Gas6-stimulated AKT phosphorylation was decreased after treatment with UNC569.
We did not anticipate significant changes in AKT activation in the presence of Gas6 or after
treatment with UNC569 in Jurkat cells since in these cells AKT is constitutively active due
to a mutation in PTEN, a phosphatase that regulates AKT activity (34). These data
demonstrate that UNC569 can effectively inhibit the activation of Mer and downstream
signaling, including the PI3K/AKT and MAPK/ERK pathways, and indicate a biochemical
mechanism by which UNC569 may influence oncogenic processes including cell growth,
proliferation and survival of ALL cells.
UNC569 induces apoptosis in ALL cell lines
To determine whether UNC569 inhibits oncogenic phenotypes in ALL cells, 697 and Jurkat
cultures were treated with UNC569 or DMSO control only and effects on proliferation and/
or survival were examined after 48 hours. Preliminary studies demonstrated efficient Mer
inhibition in ALL cells after 24 hours of treatment with UNC569, but phosphorylated Mer
levels were increased by 48 hours (Supplementary Figure 3). Thus, for the phenotypic
studies described here, UNC569 and medium were replenished after 24 hours in order to
ensure continuous Mer inhibition throughout the experiments. First, UNC569 mediated
effects on cell number in 697 and Jurkat cultures were determined using the MTT assay.
Inhibition of Mer by UNC569 decreased the number of metabolically active Jurkat and 697
cells after 48 hours in culture (Figure 3A). The 697 cell line was more sensitive to UNC569
(IC50 = 0.5 µM, 95% confidence interval = 0.35 to 0.75 µM) compared to Jurkat cells (IC50
= 1.2 µM, 95% confidence interval = 0.76 to 1.78 µM). This observation was consistent with
the relative sensitivity of these cell lines for Mer inhibition by UNC569 (Figure 2A). The
results of the MTT assay can be attributed to either a decrease in proliferation or an increase
in cell death. To distinguish between these two effects, the incidence of apoptosis in
response to treatment with UNC569 was analyzed by flow cytometry after cells were stained
with YO-PRO-1 iodide (YoPro) and propidium iodide (PI) dyes to identify early apoptotic
(YoPro+) and dead cells (YoPro+, PI+). Both cell lines exhibited a statistically significant
increase in the percentage of apoptotic and dead cells in comparison to the DMSO control in
response to treatment with UNC569 (Figure 3B). The apoptosis signaling effectors Caspase
3 and PARP were also analyzed. Jurkat and 697 cells treated with UNC569 exhibited
increased levels of cleaved Caspase 3 and cleaved PARP compared to cells treated with
DMSO control only (Figure 3C), confirming the induction of apoptosis in response to
treatment with UNC569.
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UNC569 increases sensitivity of leukemia cells to standard ALL chemotherapies
Jurkat and 697 cells were treated with the chemotherapeutic agents methotrexate (MTX) or
etoposide (VP 16) for 48 hours, either alone or in combination with UNC569 to investigate
the interaction between UNC569 and cytotoxic chemotherapies that are currently in clinical
use. Apoptotic and dead cells were detected by flow cytometry after staining with YoPro
and PI. Treatment with the low concentration of UNC569 used here was not sufficient to
induce significant cell death in the Jurkat and 697 cell lines, but resulted in a significant
increase in the percentage of dead cells in response to treatment with methotrexate or
etoposide compared to treatment with the chemotherapeutic agents alone (Figure 4A and B).
More specifically, treatment with UNC569 resulted in a significant increase in apoptotic and
dead cells in Jurkat cultures treated with methotrexate relative to cultures treated with
methotrexate alone (26.4 ± 2.9 % versus 17.5 ± 1.3 %, p = 0.03). Similarly, treatment of 697
cells with UNC569 resulted in a statistically significant increase in apoptotic and dead cells
compared with etoposide alone (43.3 ± 2.6 % versus 33.03 ± 0.42 %, p = 0.02) and a trend
when compared methotrexate alone (28.93 ± 4.96 % versus 18.13 ± 3.63 %, p = 0.1). These
results demonstrate increased sensitivity of ALL cells to cytotoxic chemotherapies in
response to Mer inhibition with UNC569.
UNC569 decreases colony formation in ALL cell lines
To further investigate whether Mer inhibition by UNC569 resulted in changes in the
oncogenic properties of ALL cells, colony forming potential in methylcellulose-based
medium was assessed. Treatment with UNC569 (400 nM) significantly inhibited the ability
of the 697 (Figure 5A, 95.9 ± 16.8 versus 14.8 ± 12.8 colonies, p = 0.02) and Jurkat (Figure
5B, 100.1 ± 23.4 versus 25.6 ± 6.4 colonies, p = 0.04) cell lines to form colonies compared
to cells treated with DMSO control only. Both the size (Figure 5C) and the number (Figure
5D) of the colonies were decreased with increasing doses of UNC569. In contrast, Jurkat
cells treated with the control compound UNC1653 did not show any reduction of colony
formation in methylcellulose (Supplementary Figure 4). UNC1653 is a structurally to
UNC569 related negative control compound, which does not inhibit Mer (data not shown).
UNC569 inhibits Mer phosphorylation, reduces proliferation and/or survival and reduces
colony formation in BT12 pediatric rhabdoid tumor cells
We repeated similar analysis in the BT12 adherent atypical teratoid rhabdoid tumor cell line
with the aim to test whether UNC569 had anti-oncogenic effects in a pediatric solid tumor.
Western blot analysis was used to determine inhibition of phospho-Mer in response to
treatment with UNC569 in atypical teratoid rhabdoid tumor cells. BT12 cells were treated
with UNC569 and a dose-dependent inhibition Mer phosphorylation was observed (Figure
6A). To investigate whether UNC569 inhibits oncogenic phenotypes in BT12 cells,
proliferation and/or survival were examined using a MTT assay after 48 hours of treatment
with UNC569 or vehicle only. Inhibition of Mer by UNC569 significantly decreased the
number of metabolically active BT12 cells after 48 hours in culture (Figure 6B, IC50 = 0.85
µM, 95% confidence interval = 0.4 to 1.7 µM). UNC569 inhibited colony formation of 697
and Jurkat cells in methycellulose. Further colony forming potential in soft agar was
assessed to examine whether Mer inhibition by UNC569 resulted in changes in the
oncogenic properties of BT12 cells. Treatment with UNC569 (1 µM) significantly inhibited
the ability of the BT12 cell line (294.7 ± 16.6 versus 175.1 ± 28.3 colonies, p = 0.02) to
form colonies compared to cells treated with vehicle only (Figure 6C and D).
UNC569 induces disease regression in a transgenic zebrafish model
The effect of UNC569 in an in vivo model of T-ALL was examined using a transgenic
zebrafish expressing lymphocyte-specific human MYC controlled by the native zebrafish
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rag2 promoter (Figure 7A). These fish develop highly-penetrant T-cell malignancies (31).
This line was bred to a second transgenic zebrafish line with T-cell specific enhanced green
fluorescent protein (GFP) expression (32). Consequently, T-cell cancers in these animals are
GFP positive (GFP+). Leukemic zebrafish were treated continuously for 2 weeks by
immersion in 4 µM UNC569, DMSO alone, or mock-treated in water only. Images were
captured before and after treatment with UNC569, and GFP fluorescence intensity was
determined as an indicator of tumor burden. UNC569-treated animals showed ≥ 50 %
disease regression in 10/18 fish, compared to > 50 % responses in only 2/14 DMSO-treated
and 0/10 mock-treated animals, respectively (Figure 7 and Supplementary Figure 5). Tumor
burden decreased by an average of 47.8 % (Figure 7B), with only 2/18 animals having
progression during treatment. DMSO-treated fish typically had either progressive (6/14 fish)
or stable (≤ 20 % regression; 4/14 fish) disease, leading to an average tumor increase of 13.0
%. Likewise, mock-treated fish exhibited an average increase in tumor burden of 9.9 %
(Figure 7B), with 4/10 animals having outright progression and 5/10 having stable disease.
The 47.8 % reduction in tumor burden in UNC569-treated animals was statistically superior
to the 13.0 % and 9.9 % increases observed in the two control groups (p = 0.0013 and
0.0003, respectively). Even in short treatment courses against already-established cancers,
UNC569 clearly demonstrates potent in vivo efficacy as a single agent against T-ALL, with
no apparent toxicity.
Discussion
Mer contributes to leukemogenesis and progression of B- and T-cell ALL (10;11). In this
study, we have extended our previous finding of ectopic Mer expression in human ALL and
evaluated Mer inhibition as a novel therapeutic strategy for treatment of ALL. In addition, as
a critical step toward development of translational agents targeting Mer for oncology
applications, we investigated the utility of a novel, first in class Mer selective small
molecule tyrosine kinase inhibitor, UNC569, for treatment of ALL using cell culture and
zebrafish models.
The studies described here demonstrate potent inhibition of Mer by UNC569 in both B-ALL
and T-ALL cell lines. Previous studies have demonstrated activation of MAPK/ERK and
PI3K/AKT signaling pathways downstream of Mer in tumor cells and roles for these
proteins in cell survival and proliferation are well established (12;29;35;36). Consistent with
these observations, we found activation of these pathways downstream of Gas6 in the 697
and Jurkat ALL cell lines. Furthermore, treatment with UNC569 resulted in decreased
activation of downstream signaling molecules, including phospho-ERK and phospho-AKT
(Figure 2C). UNC569-mediated inhibition of Mer-dependent pro-survival pathways resulted
in dose-dependent induction of apoptosis (Figure 3B and C) and decreased colony forming
potential in methylcellulose (Figure 5). Thus, UNC569 inhibits oncogenic signaling and
oncogenic properties in leukemia cells. In addition, inhibition of Mer with UNC569 resulted
in increased cell death in response to treatment with methotrexate and etoposide (Figure 4A
and B). These data suggest that Mer inhibition may be particularly effective in combination
with cytotoxic chemotherapies, allowing for increased therapeutic response and/or reduction
of chemotherapy dose and associated potential side effects. Of note, methotrexate is used in
standard pediatric ALL chemotherapy regimens and etoposide is a major component of
relapse therapy. Similar results were recently reported for the 697 and Jurkat shRNA Mer
knockdown (12;36). A shRNA Mer knockdown led to decreased ERK/AKT activation,
increased apoptosis, a chemosensitization with commonly used chemotherapeutic agents,
and a decreased colony forming potential in methylcellulose or soft agar. Thus, these data
provide rationale for introduction of Mer TKIs into the clinic in combination with agents
that are already known to be clinically effective.
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In addition, in an effort to expand upon potential clinical utilities of UNC569, we
investigated the potential efficacy of this ligand for the treatment of ATRT. Despite some
development in the treatment of ATRT (37;38), long-term outcomes remain not optimal.
Further, current multimodality therapy regimes for ATRT are toxic and associated with
short- and long-term toxicities. ATRT is a malignancy that requires the development of
more effective and less toxic therapies to improve survival. We have demonstrated in this
study that the treatment of the ATRT cell line BT12 with UNC569 resulted in an inhibition
of Mer activation (Figure 6A), in a decrease of metabolically active cells measured by MTT
(Figure 6B) and in a reduction of the ability of colony formation in soft agar (Figure 6C and
D).
Lastly, UNC569 showed potent efficacy as a single agent in a zebrafish model of MYC-
driven T-ALL, with many animals showing significant regression of established tumors after
only two weeks of treatment (Figure 7 and Supplementary Figure 5). Notably, toxicity was
not observed in these in vivo assays. Taken together these results suggest that Mer inhibition
may have utility as a single-agent and may also synergize with standard chemotherapeutics
to enhance cancer cell death in both solid tumors and hematopoietic malignancies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chemical structure of UNC569
Chemical structure of the Mer tyrosine kinase inhibitor UNC569 based on the
pyrazolopyrimidine scaffold.
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Figure 2. UNC569 inhibits Mer phosphorylation and downstream signalling in acute
lymphoblastic leukemia cells
(A) Jurkat and 697 cell cultures were treated with the indicated concentrations of UNC569
for 1 hour. Pervanadate was added to cell cultures for 3 minutes to stabilize the
phosphorylated form of Mer. Mer was immunoprecipitated from cell lysates and Mer
phospho-protein (p-Mer) and Mer total-protein (Mer) were detected by western blot. (B)
Relative levels of p-Mer and Mer proteins were determined. Mean values +/− standard error
derived from 4 independent experiments are shown. (C) Jurkat and 697 cell cultures were
incubated in serum-free medium for two hours followed by additional 90-minutes in the
presence of UNC569 (1 µM) or DMSO control. Cells were then stimulated with (+) or
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without (−) 200 nM rhGas6 and phosphorylated AKT (p-AKT), AKT, phosphorylated
ERK1/2 (p-ERK), and ERK1/2 proteins were detected in whole-cell lysates by western blot
analysis. GAPDH protein was detected as a loading control. Numbers on the left indicate the
location of molecular weight (kD) markers. Immunoblots are representative of at least three
independent experiments.
Christoph et al. Page 14













Figure 3. UNC569 reduces proliferation and/or survival and induces apoptosis in ALL cells
Cells were cultured at optimal density (3 × 105/ml) such that nutrients would not be limiting
and treated with the indicated concentrations of UNC569. After 24 hours, cells were
harvested and cultured in fresh medium containing the indicated concentrations of UNC569
for an additional 24 hours. (A) Relative numbers of metabolically active cells were
determined by MTT assay. Mean values and standard errors derived from 3 independent
experiments are shown. (B) Cells were stained with YO-PRO-1 iodide (YoPro) and
propidium iodide (PI). Apoptotic (YoPro+) and dead (YoPro+, PI+) cells were identified by
flow cytometry. Mean values +/− standard errors derived from 3 independent experiments
are shown. (C) Whole-cell lysates were prepared and the indicated proteins were detected by
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western blot. Actin was detected as a loading control. Western blots are representative of 3
independent experiments.
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Figure 4. Treatment with UNC569 results in an increase in chemosensitivity of ALL cells
Jurkat (A) or 697 (B) cells were exposed to etoposide (VP 16) and/or methotrexate (MTX)
alone and in combination with UNC569 (500 nM) for 48 hours. Apoptotic and dead cells
were identified by flow cytometric analysis of cells stained with YO-PRO-1 iodide and
propidium iodide. Representative flow cytometric profiles are shown. Mean values +/−
standard errors are derived from at least 3 independent experiments.
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Figure 5. UNC569 reduces colony formation in Jurkat and 697 cell lines
Cells were plated in methylcellulose in the presence of the indicated concentrations of
UNC569 or DMSO control only. Every 48 hours, fresh culture medium containing UNC569
or DMSO was added. Colonies were counted after eight days. Long-term colony growth of
697 (A) and Jurkat (B) cells in methylcellulose is shown. Mean values +/− standard errors
were derived from 3 independent experiments. (C) Representative colonies from the Jurkat
and 697 cell lines after treatment with the indicated concentrations of UNC569 or DMSO
control only. Single colony pictures were generated using a Nikon Eclipse TS100
microscope with Nikon Plan 10X, numerical aperture 0.25 objective lens and with a Nikon
Digital Sight DS-L2 camera equipped with Firmware DS-L2 Ver4.60. (D) Representative
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fields from methylcellulose cultures of the Jurkat and 697 cell lines after treatment with
UNC569 or DMSO control only. Bright field images were taken with a spinning disk
confocal 3I Marianas based on a inverted Zeiss Axio Observer Z1. A CoolSnap HQ2 camera
featuring 1392 × 1040 imaging pixels via a 5× Zeiss air objective was used. As imaging
acquisition software Slidebook 5.0 was utilized.
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Figure 6. UNC569 inhibits Mer phosphorylation, reduces proliferation and/or survival and
reduces colony formation in BT12 pediatric rhabdoid tumor cells
(A) Phosphorylated Mer (p-Mer) and Mer levels were evaluated by western blot following
treatment with UNC569. BT12 cell cultures were treated with the indicated concentrations
of UNC569. Pervanadate was added to cultures for 3 minutes to stabilize the phosphorylated
form of Mer. Cells were lysed, immunoprecipitated with polyclonal C-terminal Mer
antibody N-14 and subjected to SDS-polyacrylamide gel electrophoresis. Gels with
electrophoresed, Mer immunoprecipitates were transferred and blotted with phosphotyrosine
antibody or back blotted with the NIH anti-Mer polyclonal. (B) UNC569 reduces
proliferation and/or survival of BT12 cells. These data were obtained using the MTT assay.
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Cell cultures were treated with the indicated concentrations of UNC569 for 48 hours and
relative cell numbers were determined. Mean values +/− standard errors derived from 3
independent experiments are shown. (C) UNC569 reduces long-term colony growth of
BT12 cells in soft agar assay. Cells were plated in soft agar in the presence of the indicated
concentrations of UNC569. Mean values +/− standard errors derived from 3 independent
experiments are shown. (D) Representative pictures from BT12 soft agar cultures treated
with the indicated concentrations of UNC569 or DMSO control only. Pictures are scans
made with Perfection V700 Scanner.
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Figure 7. UNC569 induces disease regression in a transgenic zebrafish model
Zebrafish with GFP+ T-lymphoblastic cancers caused by transgenic human MYC were
treated with 4 µM UNC569, DMSO control, or mock-treated for 2 weeks. (A) Images at top
show the same fish (Myc1) before (left) and after (right) 4 µM UNC569 treatment × 14 days.
To quantify tumor burden, GFP intensity was reconfigured as a 3 dimensional plot (images
and graph below) and integrated for volume. Pre-treatment plots were assigned GFP scores
= 100 %; post- (day 14) treatment scores reflect % of original GFP intensity remaining (i.e.,
Myc1 post GFP score = 8.8 %, or 91.2 % regression). Myc37 images show a mock-treated
fish with stable disease (pre GFP score = 100 %, post = 99.9 %). (B) UNC569-treated fish (n
= 18) had average regressions of 47.8 %. Vehicle (n = 14) and mock (n = 10) treatments had
statistically significant progressions of 13.0 % and 9.9 % (UNC569 vs. DMSO, p =
0.0013**; UNC569 vs. mock, p = 0.0003***).
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